Micropos Medical (MPOS) Q1 2025 earnings summary

Executive summary

• Net sales increased to 2,631 TSEK from 813 TSEK year-over-year, driven by new customer orders and installations of Raypilot System in several European clinics.

• The period marked a key step in business development, with Raypilot System gaining traction as a clinical standard rather than just a research tool.

• Precisionstudien, a major multicenter clinical study, commenced with the first patient treated in March, aiming to validate the efficacy of SBRT with Raypilot.

• A fully subscribed rights issue was initiated, expected to raise 25.2 MSEK post-period, to support sales, marketing, and regulatory activities.

Financial highlights

• Net sales rose to 2,631 TSEK (813 TSEK) compared to the same quarter last year.

• Operating loss was -5,330 TSEK (-5,239 TSEK) and net loss after financial items was -5,516 TSEK (-5,254 TSEK) year-over-year.

• Cash flow for the period was -4,351 TSEK (16,925 TSEK), with cash and cash equivalents at 3,617 TSEK (22,492 TSEK) at period end.

• Equity at period end was 29,728 TSEK (25,705 TSEK); result per share was -0.04 SEK (-0.03 SEK).

• Solid equity ratio of 81% (79%) and high liquidity ratio of 470% (404%).

Outlook and guidance

• Future prospects are positive, with SBRT expected to become standard care, increasing demand for motion monitoring solutions like Raypilot.

• Precisionstudien is anticipated to drive future demand, with initial results expected within two years.

• Focus remains on business momentum, clinical evidence generation, and completion of MDR certification by autumn 2025.